Germany imported 201,094 kg of medical cannabis in 2025 and still relied on external processing, release, and import capacity.[1][2] That scale tells you where the demand sits. It does not tell you whether a given batch can survive processor intake.
GACP status opens the farm-side file.[3] Processor intake still turns on methods, document format, traceability, and whether the batch can enter a European manufacturing route without being rebuilt at the door.[4][5][2]
That gap is where the route usually narrows. A farm can clear one screen and still stall at the next.
The route file is narrower than the market narrative
Market commentary often starts from supply potential, acreage, or the size of the licensed field. The route starts from a smaller question. Can the processor accept the batch that is actually being offered?[2][5]
The first useful route screen therefore sits closer to the processor than to the headline market story.
Germany rewards the route that is already documented
German imports rose from 72,706 kg in 2024 to 201,094 kg in 2025.[1] Pharmacy prices fell from EUR8.33 per gram in January 2025 to EUR5.23 in December while listed flower products rose from 468 to 724.[8]
That combination raises the value of a clean route file. More volume and lower price leave less room for avoidable quality or documentation failure.
Public country tables answer a different question
BfArM publishes German import totals by country movement.[1] That is useful market data because it shows where released product entered Germany. It is a weaker guide to cultivation origin once flower passes through EU-GMP processing before release.[2]
The route therefore needs two reads at once: public demand-side movement and the operating file that still has to keep cultivation origin legible after processing.
Processor intake sits above GACP
The processor is reading a different file from the farm. GACP records show cultivation discipline and traceability at origin.[3] The processor is checking whether the batch can enter a manufacturing route without reopening every analytical, documentary, and identity question at the door.[4][5]
That is where first submissions often fail. The farm prepared around the certificate it already had. The processor reviews against the intake standard it already runs.
The first batch is where the gap becomes visible
The route usually does not fail in a pitch deck or a sourcing call. It fails when the first sample, first batch file, or first processor review forces both sides to read the same material at the same time.[4][2]
Methods, records, and file structure start to matter in a different way at that point. A route can look commercially real for months and still turn out to be operationally thin.
"The route starts with the smaller file, not the larger story."— BfArM import data, EudraLex documentation rules, and BfArM trader guidance
The same file supports toll processing now and site preparation later
The farms that want a route into Germany now usually begin with toll processing. Some also want a longer build toward on-site EU-GMP readiness. The work is not identical, though the file grows from the same spine: current SOPs, controlled records, accepted methods, and a batch package that survives outside review.[4][5]
That longer path should be described carefully. It is site preparation for later EU-GMP readiness, not a claim that certification is close at hand.
The route starts with the smaller file
Primary Sources
- BfArMMedizinalcannabisverkehr – Ein-/Ausfuhr↗
- BfArMHinweise fuer Haendler nach § 4 MedCanG (Stand 09/25)2025-09↗
- EDQM / European PharmacopoeiaCannabis flower monograph and related quality standards2025
- European CommissionEudraLex Volume 4 - Chapter 4 Documentation↗
- European CommissionEudraLex Volume 4 - Annex 16 Certification by a Qualified Person and Batch Release↗
- Gesetze im InternetMedizinal-Cannabisgesetz (MedCanG)↗
- Gesetze im InternetArzneimittelgesetz § 72 - Einfuhrerlaubnis↗
- High Times, citing Bloomwell / CannamonitorGermany's Medical Cannabis Problem Is That It Worked2025-12↗